BioAge Labs, Inc.

NASDAQ:BIOA

Biotechnology

Healthcare
$4.77 +2.35%

+$0.47 today

Market cap
$179.59M
Beta
0.95
P/E (TTM)
-9.7
EPS (TTM)
-$2.12
52W Low $4.07High $24.00

Volume 0.64M

Average 0.46M

BIOA Purchases of Investments

Cash used to buy marketable securities and other investments.

BioAge Labs, Inc.NASDAQ: BIOA

Purchases of Investments · Q1 FY2026 · quarter ended Mar 2026

Purchases of investments grows, but more slowly than its trailing trend

Q1 FY2026 purchases of investments of $80.21M (cash outflow) rose 3.4% year over year, behind the +102.9% change in trailing-twelve-month purchases of investments. Sequentially, it rose 99.0% from the prior quarter.

Context

  • Purchases of investments amounted to 1720.4% of revenue in FY2025.
  • Purchases of investments increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from +3.4% toward the trailing-twelve-month pace of +102.9%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$80.21M+99.0% QoQ
Last fiscal yearDec 2025
-$154.75M— YoY
LTMMar 2026
-$157.4M+102.9% YoY
Purchases of Investments past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+3.4%——
1 year———
3-year CAGR———
5-year CAGR——
10-year CAGR——

Purchases of Investments history

USD · from the cash flow

Latest · FY2025
(154.75M) USD
Year-over-year change
—

Purchases of Investments vs competitors

How BIOA compares with its peers on the latest reported figures

  • Peers report in different currencies, so purchases of investments is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +102.9% is the highest of 6, against a peer median of -42.6%.
  • Purchases of investments amounts to 1525.8% of revenue for BIOA, versus a peer median of 0.0%.
BIOA Competitors
Purchases of Investments for BIOA and competitors
Company Period LTM YoY 3-year CAGR% of revenue
AVIRAtea Pharmaceuticals, Inc.LTM Mar 2026$233.85M USD-43.9%-19.7%—
ALLOAllogene Therapeutics, Inc.LTM Mar 2026$189.73M USD-42.6%-17.7%—
BIOABioAge Labs, Inc.LTM Mar 2026$157.4M USD+102.9%—1525.8%
CABACabaletta Bio, Inc.LTM Mar 2026$99.04M USD—+25.8%—
TKNOAlpha Teknova, Inc.LTM Mar 2026$19.12M USD-40.7%—45.7%
ACBAurora Cannabis Inc.LTM Mar 2026CA$126.32K CAD——0.0%
EDITEditas Medicine, Inc.LTM Mar 2026$0 USD-100.0%—0.0%
LFCRLifecore Biomedical, Inc.LTM Mar 2026$0 USD——0.0%
CGCCanopy Growth CorporationLTM Mar 2026CA$0 CAD+100.0%—0.0%
HUMAHumacyte, Inc.LTM Mar 2026$0 USD——0.0%
Peer median (excluding BIOA) —-42.6%-17.7%0.0%

Competitors are the stored peer set for BIOA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(39.72M)(63.85M)(71.11M)(80.61M)
Depreciation & Amortization129K162K167K213K
Deferred Income Tax0000
Stock-Based Compensation2.54M3.02M6.98M11.69M
Change in Working Capital795K6.71M11.18M(11.83M)
Accounts Receivables000(769K)
Inventory0000
Accounts Payables994K(393K)6K788K
Other Working Capital(199K)7.1M11.17M(11.85M)
Other Non-Cash Items77K16.6M1.27M(1.1M)
Operating Cash Flow(36.18M)(37.36M)(51.52M)(81.63M)
Capital Expenditures(103K)(166K)(366K)(719K)
Acquisitions (Net)0000
Purchases of Investments0(100K)0(154.75M)
Sales of Investments00060.25M
Other Investing Activities0000
Investing Cash Flow(103K)(266K)(366K)(95.22M)
Debt Repayment2.5M35M(6M)(6M)
Common Stock Issued44K0221.62M17.87M
Common Stock Repurchased0000
Dividends Paid0000
Other Financing Activities(45K)(59K)(4.42M)(400K)
Financing Cash Flow2.5M34.94M381.2M11.47M
Effect of Forex Changes246K081K(87K)
Net Change in Cash(33.54M)(2.69M)329.39M(165.46M)
Free Cash Flow(36.28M)(37.53M)(51.89M)(82.35M)

BioAge Labs, Inc.

NASDAQ:BIOA

Intrinsic Alpha fair value

Locked

Current Price

$4.77

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.